tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

IMMX Stock Latest News

Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial
The FlyImmix Biopharma announces data from four patients in NEXICART-2 U.S. trial
3d ago
IMMX
Immix Biopharma announces publication of NXC-201 clinical results
PremiumThe Fly
Immix Biopharma announces publication of NXC-201 clinical results
6d ago
IMMX
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
PremiumThe Fly
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
12d ago
IMMX
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
PremiumThe Fly
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
3M ago
IMMX
Immix Biopharma announces three more sites for NEXICART-2 trial
PremiumThe Fly
Immix Biopharma announces three more sites for NEXICART-2 trial
4M ago
IMMX
Immix Biopharma awarded $8M CLIN2 grant
PremiumThe FlyImmix Biopharma awarded $8M CLIN2 grant
5M ago
IMMX
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
Premium
The Fly
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
6M ago
IMMX
Immix Biopharma initiated with a Buy at H.C. Wainwright
Premium
The Fly
Immix Biopharma initiated with a Buy at H.C. Wainwright
6M ago
IMMX
Immix Biopharma Shareholders Back Growth and Governance Changes
PremiumCompany Announcements
Immix Biopharma Shareholders Back Growth and Governance Changes
6M ago
8K
IMMX
Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
PremiumThe Fly
Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
8M ago
IMMX
Immix Biopharma management to meet with B. Riley
PremiumThe Fly
Immix Biopharma management to meet with B. Riley
8M ago
IMMX
Immix Biopharma management to meet with B. Riley
PremiumThe Fly
Immix Biopharma management to meet with B. Riley
8M ago
IMMX
Immix Biopharma: EC grants orphan drug designation to NXC-201
PremiumThe FlyImmix Biopharma: EC grants orphan drug designation to NXC-201
8M ago
IMMX
Immix Biopharma says ‘on track’ to dose NXC-201 patients in U.S.
Premium
The Fly
Immix Biopharma says ‘on track’ to dose NXC-201 patients in U.S.
8M ago
IMMX
Immix announces Memorial Sloan Kettering as lead site for NXC-201 trial
Premium
The Fly
Immix announces Memorial Sloan Kettering as lead site for NXC-201 trial
9M ago
IMMX
Immix Biopharma: EC grants orphan drug designation to NXC-201
PremiumThe Fly
Immix Biopharma: EC grants orphan drug designation to NXC-201
11M ago
IMMX
Immix Biopharma Announces New Offering, Sparks Investor Interest
PremiumCompany Announcements
Immix Biopharma Announces New Offering, Sparks Investor Interest
11M ago
8K
IMMX
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
PremiumCompany Announcements
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
11M ago
8K
IMMX
Immix Biopharma 5.5M share priced at $2.71
PremiumThe Fly
Immix Biopharma 5.5M share priced at $2.71
11M ago
IMMX
Immix Biopharma Suspends Stock Offering Pending New Prospectus
PremiumCompany AnnouncementsImmix Biopharma Suspends Stock Offering Pending New Prospectus
11M ago
8K
IMMX
Immix Biopharma announces common stock offering, no amount given
Premium
The Fly
Immix Biopharma announces common stock offering, no amount given
11M ago
IMMX
Immix Biopharma ‘applauds’ FDA labeling change notification for CAR-T products
Premium
The Fly
Immix Biopharma ‘applauds’ FDA labeling change notification for CAR-T products
11M ago
IMMX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >